10 May Variability of Biomarkers Used In Clinical Trials May Cloud Outcomes

MedicalResearch.com Interview with:
Alan H.B. Wu, PhD, DABCC
Professor Laboratory Medicine
Chief, Clinical Chemistry Laboratory
University of California San Francisco, CA

Medical Research: What is the background for this study? What are the main findings?

Response: Clinical trials are conducted for validation of novel biomarkers.  There is considerable heterogeniety in the quality design and documentation of findings. This can have a major impact on the conclusions rendered.

Medical Research: What should clinicians and patients take away from your report?

Response: Clinicians should be aware of study limitations in the interpretation of the results of clinical trials.

Medical Research: What recommendations do you have for future research as a result of this study?

Response: I recommend better adherence to published guidelines on how to design, conduct, and publish a clinical trial for biomarkers.

Citation:

Analytical validation of novel cardiac biomarkers used in clinical trials

Alan H.B. Wu, PhD, DABCC^,
American Heart Journal Volume 169, Issue 5, May 2015, Pages 674–683

[wysija_form id=”3″]

MedicalResearch.com Interview with: Alan H.B. Wu, PhD, DABCC (2015). MedicalResearch.com Interview with: Alan H.B. Wu, PhD, DABCC 

Last Updated on May 10, 2015 by Marie Benz MD FAAD